Disease-associated dysbiosis and potential therapeutic role of Akkermansia muciniphila, a mucus degrading bacteria of gut microbiome

• Published in: Folia microbiologica 2022-12, Vol.67 (6), p.811-824
• Main Authors: Aggarwal, Vidushi, Sunder, Sushant, Verma, Smita Rastogi
• Format: Article
• Language: English
• Subjects: Akkermansia muciniphila; Applied Microbiology; Bacteria; Biodegradation; Biomarkers; Biomedical and Life Sciences; Chemical compounds; COVID-19; Cystic fibrosis; Degradation; Diabetes mellitus (non-insulin dependent); Digestive system; Disease; Dysbacteriosis; Environmental Engineering/Biotechnology; Gastrointestinal tract; Health services; Homeostasis; Immunity; Immunology; Intestinal microflora; Life Sciences; Metabolic disorders; Metabolism; Microbiology; Microbiomes; Microbiota; Mucin; Mucus; Pharmacology; Precision medicine; Probiotics; Respiratory diseases; Review
• ISSN: 0015-5632; 1874-9356
• DOI: 10.1007/s12223-022-00973-6

The unique functionality of Akkermansia muciniphila in gut microbiota indicates it to be an indispensable microbe for human welfare. The importance of A. muciniphila lies in its potential to convert mucin into beneficial by-products, regulate intestinal homeostasis and maintain gut barrier integrity. It is also known to competitively inhibit other mucin-degrading bacteria and improve metabolic functions and immunity responses in the host. It finds a pivotal perspective in various diseases and their treatment. It has future as a promising probiotic, disease biomarker and therapeutic agent for chronic diseases. Disease-associated dysbiosis of A. muciniphila in the gut microbiome makes it a potential candidate as a biomarker for some diseases and can provide future theranostics by suggesting ways of diagnosis for the patients and best treatment method based on the screening results. Manipulation of A. muciniphila in gut microbiome may help in developing a novel personalized therapeutic action and can be a suitable next generation medicine. However, the actual pathway governing A. muciniphila interaction with hosts remains to be investigated. Also, due to the limited availability of products containing A. muciniphila , it is not exploited to its full potential. The present review aims at highlighting the potential of A. muciniphila in mucin degradation, contribution towards the gut health and host immunity and management of metabolic diseases such as obesity and type 2 diabetes, and respiratory diseases such as cystic fibrosis and COVID-19.